A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

A more comprehensive multiethnic genetic risk score strongly predicted new cases of type 2 diabetes, including for people ...

"Obesity is associated with inflammation, diabetes and high blood pressure, which are all independent risk factors for dementia." In addition to aging, other risk factors include genetics ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future risk of developing serious ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Gut microbiota plays a critical role in childhood obesity by influencing energy metabolism, inflammation, and appetite ...

The medical journal The Lancet recently published a detailed consensus statement classifying obesity as a disease. The ...

It raises questions about the different impacts of acquired and genetic obesity on cancer risk, the role of aging in these effects, and the potential vicious cycle of deteriorating obesity ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...